|
 |
Dr. Karen Fiumara
Brigham and Women's Hospital
Boston, MA
|
|
|
DVT Prophylaxis in High Risk Med/Surg Patients
Dr. Karen Fiumara, Patient Safety Officer at Brigham and Women’s Hospital will discuss anticoagulation prophylaxis in high risk patients in the inpatient environment. Her presentation will include steps taken by Brigham and Women’s Hospital to increase physician awareness of VTE risk and overcome resistance to prophylaxis.
|
|
 |
Dr. Victoria Lambert
William W. Backus Hospital
Norwich, CT |
|
|
Cases in Bridge Therapy
Dr. Victoria Lambert will discuss the risks and benefits of anticoagulation bridge therapy, analyze cases to determine the appropriateness of bridge therapy, formulate a case specific plan and develop case-specific monitoring parameters.
|
|
 |
Dr. Mark Wurster
MD, FACP.
The Ohio State University Medical Center |
|
|
Patient Self Testing: Opportunities and Challenges
Dr. Mark Wurster of The Ohio State University Medical Center discusses the challenges and opportunities surrounding Patient Self Testing including its clinical, workflow and financial impact.
Dr. Wurster is the Director of the OSU Hemochromatosis Program, Director of the National Physician Education Initiative, Iron Disorders Institute, the Lead Physician on the Joint Commission Anticoagulation Task Force, OSUMC and a member of the Steering Committee for National Inpatient Benchmarking Project, University Health Consortium.
|
|
| |
Dr. Brian Musiak
Clinical Pharmacist
William W. Backus Hospital
|
|
|
Dr. Brian Musiak discusses the role of extending anticoagulation prophylaxis post-hospitalization to prevent thrombotic events in high risk patients. He will discuss the type of patient posing a high risk and the drug therapy options for extended prophylaxis.
|
|
 |
Dr. Michael Smith
Clinical Coordinator
William W.Backus Hospital
|
|
|
Dr. Michael Smith, Clinical Coordinator at the William W. Backus Hospital discusses the role of INR, Factor Anti-Xa and PTT in monitoring anticoagulation therapy. Dr. Smith describes the monitoring parameters for specific anticoagulation therapies, the counseling points for patients on chronic anticoagulation therapy and formulates case-specific monitoring plans.
|
|
 |
Dr. Philip Hritcko
University of Connecticut School of Pharmacy
|
|
Dr. Philip Hritcko will discuss the pharmacokinetic and pharmacodynamic mechanisms for warfarin drug interactions. This webinar will include actual case studies in addition to the presentation of clinical data.
Dr. Hritcko received his B.S. and Doctor of Pharmacy degrees from Albany College of Pharmacy. He is currently Director, Experiential Education and Assistant Clinical Professor of Pharmacy Practice at the University of Connecticut School of Pharmacy.
In addition to his responsibilities at the University of Connecticut School of Pharmacy, Dr. Hritcko practices as a clinical pharmacist at the William W. Backus Hospital Anticoagulation Clinic located in Norwich Connecticut.
Please note that the archived version of this webinar does not carry CE credits.
|
|
 |
John Fanikos, RPh, MBA
Brigham and Women's Hospital
|
|
|
Listen to John Fanikos, RPh, MBA, Assistant Head of Pharmacy at the Brigham and Women's Hospital in Boston discuss the changing landscape in the area of new thromboembolic inhibitors.
|
|
|
Dr. Mark Wurster
MD, FACP.
The Ohio State University Medical Center |
|
|
The University Health Consortium recently conducted a trial among 31 anticoagulation clinics in their membership. Only one achieved "Better Performer" status. Hear Dr. Mark Wurster talk about how the Ohio State University Medical Center catapulted to the top using the principles and methodologies of CoagClinic, Standing Stone's industry-leading anticoagulation management software.
Dr. Wurster is the Director of the OSU Hemochromatosis Program, Director of the National Physician Education Initiative, Iron Disorders Institute, the Lead Physician on the Joint Commission Anticoagulation Task Force, OSUMC and a member of the Steering Committee for National Inpatient Benchmarking Project, University Health Consortium.
|
|
 |
Lynn B. Oertel
MS, ANP, CACP
|
|
|
Lynn B. Oertel, member of the AC Forum Board of Directors and co-editor and chapter author of the textbook: Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines, 3rd Edition discusses her experience with implementation of protocols to meet National Patient Safety Guideline 3E around medication management.
|
|
|
Dr. Jeanine Walenga
|
Dr. Craig Jackson
|
|
|
|
Dr. Craig Jackson and Dr. Jeanine Walenga discuss heparin biosimilars. The webinar addresses the mechanism of heparin anticoagulants in vivo and in vitro, low molecular weight heparin, unfractionated heparin, heparin adulteration and safety concerns.
Dr. Jackson: Professor of Biological Chemistry and Associate Professor, Internal Medicine, Washington University School of Medicine, St. Louis.
Dr. Walenga: Professor of Thoracic-Cardiovascular Surgery and Pathology, Loyola University, Chicago.
|
|
|
|
 |
Responsibility
At Standing Stone, our business is software development, but we think it is our responsibility to support our customers and the anticoagulation community at large by promoting the dissemination of scientific and clinical findings and fostering discussions that advance our field.
Improved outcomes and decreased risk can be facilitated by great software, but that is only one piece of the puzzle. The clinical information built into that software and the judgement of the practitioner are critically important. Understanding the most recent findings, the protocols that result in best practices and the science of our field benefits us all.
We hope that the ongoing webinar series that we provide will help the entire anticoagulation community. Please pass along the information to colleagues and co-workers.
If you have any suggestions for topics please let me know. I'll do my best to find the right speaker or panel.
Happy listening,
Barbara Chopin
Manager of Marketing Communications
|
|
|